Therapy resistance in AML is mediated by cytoplasmic sequestration of the transcriptional repressor IRF2BP2
Althoff, M. J.; Minhajuddin, M.; Stevens, B.; Gillen, A. E.; Gipson, S.; Patel, S. B.; Shelton, I. T.; Miller, R.; Vujovic, A.; Krug, A.; Young, T.; Showers, W. M.; Dzieciatkowska, M.; Stephenson, D.; Tyagi, A.; Ellegast, J. M.; Wright, T.; Stegmaier, K.; Opferman, J. T.; D'Alessandro, A.; Smith, C. A.; Jordan, C. T.
Show abstract
While the development of venetoclax with azacitidine (ven/aza) has improved AML therapy, drug resistance remains a major challenge. Notably, primary ven/aza-resistant AML are frequently reliant on MCL1, however, the underlying mechanisms remain unclear. Co-immunoprecipitation of MCL1 from ven/aza-resistant AML samples coupled with mass spectrometry analysis identified the transcriptional repressor Interferon Regulatory Factor 2 Binding Protein 2 (IRF2BP2) as an MCL1 binding partner. This interaction results in cytoplasmic IRF2BP2 localization and loss of transcriptional repression within ven/aza-resistant leukemic stem cells (LSC). Consequently, ven/aza-resistant LSC have increased IRF2BP2 target gene expression, including acyl-CoA synthetase long-chain family member 1 (ACSL1), an essential rate-limiting enzyme for fatty acid oxidation (FAO). Inhibition of ACSL1 functionally impaired ven/aza-resistant LSC through a depletion of long-chain acyl-carnitine metabolites and FAO. Collectively, these data provide evidence for a previously undescribed mechanism by which MCL1 mediates IRF2BP2 cytoplasmic sequestration and consequent de-repression of ACSL1, thereby promoting ven/aza-resistance in AML.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network 98%
- AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML 97%
- Mapping AML heterogeneity – multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses 97%
Similar papers in this journal
- Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia 98%
- Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition 97%
- Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia 97%
Similar papers in this journal
- Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes 97%
- Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia 96%
- Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications 96%
Similar papers in this journal
- BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 97%
- A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML 97%
- MondoA Drives Malignancy in cALL through Enhanced Adaptation to Metabolic Stress 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.